Biotechnology Partners to Accelerate Cancer Drug Development

(London, UK) and GENova (New York, NY, USA), expect that this synergistic approach will both reduce Genova's research and development budget while significantly increasing its distribution network.

Research and development teams from both companies will be examining their current intellectual property portfolios to identify mutually beneficial points of cooperation to facilitate attainment of their drug targets and to assess the possibility of making stronger, better, combined products by coordinating their biotechnologies.

"By combining our efforts with Beckpharma's, we are casting a wider net when it comes to sourcing new cancer drug targets," said Aaron Whiteman, CEO of GENova. "Beckpharma has close relationships with academic research institutions around the world, and now, through this collaboration, their industry contacts become ours, and vice versa. This is a positive step for GENova. Through our collaboration with Beckpharma we are gaining access to their technologies and relationships, and we hope to leverage that to bring our patents to market faster, and thus start reaping payments on our potential blockbuster drug patents."

Related Links:
Beckpharma
GENova